<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">8688340</article-id><article-id pub-id-type="pmc">2074573</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Stewart</surname><given-names>H. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Forrest</surname><given-names>A. P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Everington</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>McDonald</surname><given-names>C. C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dewar</surname><given-names>J. A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hawkins</surname><given-names>R. A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Prescott</surname><given-names>R. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>George</surname><given-names>W. D.</given-names></name></contrib></contrib-group><aff>Scottish Cancer Trials Office, Medical School, University of Edinburgh, UK.</aff><pub-date pub-type="ppub"><month>7</month><year>1996</year></pub-date><volume>74</volume><issue>2</issue><fpage>297</fpage><lpage>299</lpage><abstract><p>In 1985 a second randomisation was initiated for women in the treatment arm of the Scottish Tamoxifen Trial either to stop tamoxifen at 5 years or to continue indefinitely. A preliminary analysis of outcome in 342 patients at a median follow-up of 6 years suggests that a worthwhile gain in disease control from continuing adjuvant tamoxifen beyond 5 years is unlikely. [Hazard ratio for events (relapse or death without relapse) is 1.27, 95% CI = 0.87 - 1.85.] There is a suggestion that therapy for longer than 5 years may increase the risk of endometrial carcinoma (P = 0.064).</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00018-0137.tif" xlink:title="scanned-page" xlink:role="297" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00018-0138.tif" xlink:title="scanned-page" xlink:role="298" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00018-0139.tif" xlink:title="scanned-page" xlink:role="299" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

